Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 21,412 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Conditions
Multiple Myeloma
Interventions
Infusion of Activated & Expanded Autologous T Cells
Procedure
Lead sponsor
Xcyte Therapies
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Not applicable Interventional Results available

SAbR For Oligometastatic Renal Cell Carcinoma

NCT02956798
Conditions
Oligometastatic Renal Cell Carcinoma
Interventions
Stereotactic ablative body radiation (SABR)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Melanoma
Interventions
ZK-EPO
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Conditions
Ovarian Cancer
Interventions
Sorafenib, Topotecan
Drug
Lead sponsor
Daniela Matei, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Conditions
Leukemia
Interventions
Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Conditions
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Dasatinib, Dexamethasone, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), Prednisone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Obesity
Interventions
GLY-200, Placebo
Drug
Lead sponsor
Glyscend, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Clearwater, Florida • Ocoee, Florida • Marrero, Louisiana + 2 more
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Squamous Cell Carcinoma, Head And Neck
Interventions
WNT974
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alopecia Areata
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 9 more
Conditions
Breast Cancer
Interventions
Margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Plantation, Florida + 3 more
Conditions
Cerebral Cavernous Malformation
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson Disease
Interventions
Biological/Vaccine: Allogeneic HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
Interview, Questionnaire Administration
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
325
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 204 more
Terminated Phase 2 Interventional Results available

Gemcitabine Plus Ascorbate for Sarcoma in Adults

NCT03468075
Conditions
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions
Ascorbate, Gemcitabine
Drug
Lead sponsor
Mohammed Milhem, MBBS
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975
Conditions
Hookworm Infections
Interventions
Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
Biological · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Paclitaxel / Carboplatin, bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Whittier, California + 14 more
Conditions
Spinal Cord Injury
Interventions
Autologous Incubated Macrophages (cell therapy)
Procedure
Lead sponsor
Proneuron Biotechnologies
Industry
Eligibility
16 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Englewood, Colorado • Atlanta, Georgia • Newark, New Jersey + 3 more